Skip to main content

Table 4 Multivariate analysis of 30-day all-cause mortality due to neutropenic pneumonia

From: Treatment of community-onset pneumonia in neutropenic cancer patients: β-lactam monotherapy versus combination antibiotic regimens

Variables

Univariate analysis

Multivariate analysis

HR (95% CI)

P-value

HR (95% CI)

P-value

Lung cancer

3.55 (1.13–11.15)

0.030

1.60 (0.30–8.63)

0.586

Palliative setting

4.83 (1.09–21.43)

0.038

58.61 (0.26–13,356.90)

0.142

Duration of neutropenia

1.08 (1.03–1.15)

0.003

1.27 (1.05–1.53)

0.013

CRP

1.04 (1.00–1.08)

0.035

1.06 (1.00–1.11)

0.021

MASCC risk index

0.80 (0.68–0.95)

0.010

0.80 (0.65–0.99)

0.042

Combination therapy

0.27 (0.09–0.85)

0.025

0.85 (0.20–3.67)

0.827

Types of β-lactams

 Cefepime

0.28 (0.10–0.81)

0.019

0.64 (0.17–2.46)

0.518

 Ceftazidime

2.05 (0.58–7.25)

0.268

  

 Piperacillin-tazobactam

1.42 (0.40–5.02)

0.589

  

 Carbapenem

5.95 (1.89–18.70)

0.002

0.28 (0.01–50.00)

0.631

  1. Abbreviations: CI confidence interval, CRP C-reactive protein, HR hazard ratio, MASCC Multinational Association for Supportive Care in Cancer